-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2024-511099-34-00
1
2024-12-12
B-Cell Malignancies
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-512053-24-00
4
2024-12-05
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-519067-17-00
4
2024-12-02
Locally Advanced Pancreatic Cancer
-
2023-508949-40-00
4
2024-11-29
Eosinophilic esophagitis
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2024-516591-15-00
6
2024-11-12
urinary tract infections
-
2023-510288-37-00
3
2024-11-01
Relapsed and/or refractory Acute Myeloid Leukemia
-
2023-509560-16-00
5
2024-10-29
Juvenile psoriatic arthritis (jPsA)
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2022-502075-34-00
5
2024-10-08
Generalized Myasthenia Gravis
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-510136-36-00
1
2024-09-27
Advanced Non-Hodgkin’s Lymphoma